Other research analysts have also recently issued research reports about the company. JPMorgan Chase & Co. set a $40.00 price target on Endo International PLC and gave the stock a buy rating in a research note on Tuesday, August 9th. Leerink Swann reissued a hold rating and issued a $22.00 price target (down previously from $23.00) on shares of Endo International PLC in a research note on Tuesday, August 9th. Mizuho raised Endo International PLC from a neutral rating to a buy rating and increased their price target for the stock from $16.00 to $29.00 in a research note on Friday, August 12th. Vetr cut Endo International PLC from a strong-buy rating to a buy rating and set a $19.14 price target for the company. in a research note on Thursday, July 7th. Finally, Deutsche Bank AG reissued a buy rating and issued a $30.00 price target on shares of Endo International PLC in a research note on Wednesday, June 29th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $39.32.
Endo International PLC (NASDAQ:ENDP) opened at 20.93 on Tuesday. The firm’s market cap is $4.66 billion. Endo International PLC has a 52 week low of $12.56 and a 52 week high of $72.85. The company has a 50-day moving average of $21.47 and a 200 day moving average of $21.28.
Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings results on Monday, August 8th. The company reported $0.86 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.74 by $0.12. Endo International PLC had a positive return on equity of 15.54% and a negative net margin of 25.90%. The company earned $921 million during the quarter, compared to analysts’ expectations of $873.50 million. During the same quarter in the prior year, the business posted $1.08 earnings per share. The company’s revenue for the quarter was up 25.3% compared to the same quarter last year. On average, equities analysts predict that Endo International PLC will post $4.56 earnings per share for the current year.
Hedge funds have recently modified their holdings of the stock. IFP Advisors Inc raised its stake in Endo International PLC by 103,542.9% in the second quarter. IFP Advisors Inc now owns 14,510 shares of the company’s stock valued at $226,000 after buying an additional 14,496 shares during the last quarter. Amalgamated Bank raised its stake in Endo International PLC by 240.1% in the second quarter. Amalgamated Bank now owns 28,122 shares of the company’s stock valued at $647,000 after buying an additional 19,853 shares during the last quarter. Panagora Asset Management Inc. raised its stake in Endo International PLC by 29.9% in the second quarter. Panagora Asset Management Inc. now owns 34,828 shares of the company’s stock valued at $543,000 after buying an additional 8,019 shares during the last quarter. HRS Investment Holdings LLC bought a new stake in Endo International PLC during the second quarter valued at about $312,000. Finally, Schneider Capital Management Corp bought a new stake in Endo International PLC during the second quarter valued at about $6,941,000. Institutional investors own 96.64% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.